Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

This study has been completed.
National Center for Research Resources (NCRR)
Information provided by (Responsible Party):
Ron Hall, Texas Tech University Health Sciences Center Identifier:
First received: July 16, 2010
Last updated: June 9, 2016
Last verified: June 2016
Results First Received: October 28, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Obesity
Intervention: Drug: Dapsone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited into three BMI groups to ensure a wide total body weight distribution, but only one pharmacokinetic model was analyzed with total body weight being one of the potential covariates that was assessed.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Thirty-seven patient provided consent, but only 36 started the study. One patient provided informed consent but was found to have G6PD and was not allowed to continue.

Reporting Groups

Dapsone 100 mg PO x 1 dose

Dapsone: 100 mg PO x 1 dose

Participant Flow:   Overall Study
STARTED     36  
COMPLETED     36  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

Dapsone 100 mg PO x 1 dose

Dapsone: 100 mg PO x 1 dose

Baseline Measures
Number of Participants  
[units: participants]
[units: participants]
<=18 years     1  
Between 18 and 65 years     34  
>=65 years     1  
[units: years]
Mean (Standard Deviation)
  38.2  (13.7)  
[units: participants]
Female     18  
Male     18  
Region of Enrollment  
[units: participants]
United States     36  

  Outcome Measures

1.  Primary:   Serum Clearance   [ Time Frame: 72 hours ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Ronald Hall
Organization: Texas Tech University HSC
phone: 214-358-9009

Responsible Party: Ron Hall, Texas Tech University Health Sciences Center Identifier: NCT01165840     History of Changes
Obsolete Identifiers: NCT01307930
Other Study ID Numbers: AMAIRB97
5UL1RR024982-02 ( US NIH Grant/Contract Award Number )
Study First Received: July 16, 2010
Results First Received: October 28, 2015
Last Updated: June 9, 2016
Health Authority: United States: Institutional Review Board